We compared the expression levels of ROR1 on CLL cells from these patients before therapy at SC1 with that of CLL cells obtained more than 1 year later (Sample Collection 2 (SC2)), when they were noted to have progressive increases in MRD despite continued venetoclax therapy (Fig. 1B). This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.